GenIbet is participating in “TRANSVAC-DS – Towards a sustainable European vaccine infrastructure”, a European vaccine research and development (R&D) infrastructure project coordinated by the European Vaccine Initiative (EVI) and dedicated to accelerating the development of safe, effective and affordable vaccines.
Scientist developing vaccine candidates face a number of different challenges – scientific, technical, regulatory and financial – which require a combination of knowledge, skills and technical capacities which are unlikely to be available at a single organization. By bringing together 25 partners within the European vaccine development landscape, with different backgrounds and capacities, TRANSVAC-DS aims to enable the access to innovative R&D services, technical training and state-of-the-art manufacturing facilities and facilitate the development of safe, effective and affordable vaccines.
If you are a researcher with good preliminary results, needing support to further develop vaccine candidates, apply for TRANSVAC2 Vaccine Development Services: Open call until April 15th, 2021
Required Cookies The cookies allow to customize the commercial offers that are presented to you, considering your interests. They can be our own or third party cookies. Please, be advised that, even if you do not accept these cookies, you will receive commercial offers, but do not match your preferences.
Functional Cookies The cookies offer you a more complete and personalised experience, allowing to safe preferences, showing you relevant content to your liking and send you alerts you have requested.
Advertising Cookies These cookies offer the possibility to connect to social media and share content from our website.